molecules of the month


oral, macrocyclic CDK2 inhibitor

robust activity in ovarian cancer xenograft models

AI generative modeling + opt.

ACS. Med. Chem. Lett., February 8, 2023

Regor Therapeutics Group, Shanghai, CN

QR-6401, oral, macrocyclic CDK2 inhibitor, robust activity in ovarian cancer xenograft models, REGOR THERAPEUTICS GROUP, SHANGHAI, CN
4 mins read

Overview. Cyclin-dependent kinase (CDK2) is a target of recent interest, but selectivity has been challenging to obtain. This molecule provides an interesting example of AI being applied to lead generation. Macrocycles can be challenging to design rationally, but can lead to a variety of favorable properties (e.g. in addressing resistance or brain penetration; see article on Turning Point) and novel intellectual property space. AI could potentially assist with identifying promising starting points. While the authors admit the limitations of this approach and demonstrated superiority of human design, this case study illustrates proof-of-concept for how AI can help assist lead generation by human designers and provides a practical tool for generating viable macrocyclic starting points that could be valuable in kinase…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: